United Therapeutics CORP (UTHR) — SEC Filings

Overview

United Therapeutics CORP (UTHR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: On March 30, 2026, UNITED THERAPEUTICS Corp filed an 8-K report detailing other events and financial statements. The filing includes exhibits such as financial statements and interactive data. The company's mailing and business address is 1000 SPRING ST, SILVER SPRING, MD 20910.

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 2 bullish, 29 neutral. The dominant filing sentiment for United Therapeutics CORP is neutral.

Filing Type Overview

United Therapeutics CORP (UTHR) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Recent Filings (31)

• UNITED THERAPEUTICS Corp Files 8-K — 8-K · Mar 30, 2026 Risk: low
  On March 30, 2026, UNITED THERAPEUTICS Corp filed an 8-K report detailing other events and financial statements. The filing includes exhibits such as financial
• United Therapeutics Posts Strong Q3 Revenue, Net Income Growth — 10-Q · Oct 29, 2025 Risk: medium
  United Therapeutics Corporation reported robust financial performance for the three and nine months ended September 30, 2025. Total revenues increased by 6.7% t
• United Therapeutics Files 8-K Report — 8-K · Sep 2, 2025 Risk: low
  On September 2, 2025, United Therapeutics Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits,"
• United Therapeutics Corp Files 8-K — 8-K · Aug 1, 2025 Risk: low
  On August 1, 2025, United Therapeutics Corporation entered into a material definitive agreement. The filing also includes information regarding Regulation FD di
• United Therapeutics Posts Strong Q2 Growth, Net Income Jumps 21.6% — 10-Q · Jul 30, 2025 Risk: medium
  UNITED THERAPEUTICS Corp reported robust financial performance for the second quarter ended June 30, 2025, with significant growth in revenue and net income. Re
• United Therapeutics Files 8-K: Board, Officer, and Compensation Updates — 8-K · Jun 27, 2025 Risk: low
  On June 26, 2025, United Therapeutics Corporation filed an 8-K report detailing several key events. The company announced the election of new directors and the
• United Therapeutics Files Q1 2025 10-Q — 10-Q · Apr 30, 2025 Risk: low
  United Therapeutics Corp. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quar
• United Therapeutics Proxy Statement Filed — DEF 14A · Apr 29, 2025 Risk: low
  United Therapeutics Corp filed its definitive proxy statement on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive comp
• United Therapeutics Corp Files 8-K with Material Agreements — 8-K · Apr 28, 2025 Risk: medium
  On April 25, 2025, United Therapeutics Corporation entered into a material definitive agreement and simultaneously terminated another. The company also created
• United Therapeutics Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
  United Therapeutics Corporation filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Silver Sp
• United Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
  United Therapeutics Corporation filed an 8-K on January 13, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing deta
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• United Therapeutics Q3 2024 Filing Released — 10-Q · Oct 30, 2024 Risk: medium
  United Therapeutics Corp. reported its third-quarter financial results for the period ending September 30, 2024. The company's filing details its financial posi
• SC 13G Filing — SC 13G · Oct 16, 2024
• United Therapeutics Files Q2 2024 10-Q — 10-Q · Jul 31, 2024 Risk: medium
  United Therapeutics Corp. filed its 10-Q for the period ending June 30, 2024. The company reported its financial performance for the second quarter and the firs
• United Therapeutics Approves New Equity Incentive Plan — 8-K · Jun 27, 2024 Risk: low
  United Therapeutics Corporation announced on June 26, 2024, that its Board of Directors has approved a new equity incentive award plan. This plan allows for the
• SC 13G/A Filing — SC 13G/A · Jun 10, 2024
• United Therapeutics Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 1, 2024 Risk: low
  UNITED THERAPEUTICS Corp (UTHR) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. United Therapeutics Corp filed a 10-Q report for the period ending
• United Therapeutics Corp. Files Definitive Proxy Statement — DEF 14A · Apr 29, 2024 Risk: low
  UNITED THERAPEUTICS Corp (UTHR) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Filing type: DEF 14A (Definitive Proxy Statement). Reporting p
• United Therapeutics Enters New Loan Agreement — 8-K · Mar 29, 2024 Risk: medium
  On March 29, 2024, United Therapeutics Corporation entered into a material definitive agreement, specifically a loan agreement. This agreement creates a direct
• United Therapeutics Files 8-K: Material Agreement & Financials — 8-K · Mar 25, 2024 Risk: medium
  On March 25, 2024, United Therapeutics Corporation filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclos
• United Therapeutics Files 8-K for Undisclosed Event — 8-K · Feb 27, 2024 Risk: medium
  United Therapeutics Corporation filed an 8-K on February 27, 2024, reporting an "Other Event" that occurred on February 26, 2024. The filing, identified by acce
• United Therapeutics Corp Files 2023 Annual Report on Form 10-K — 10-K · Feb 21, 2024 Risk: medium
  UNITED THERAPEUTICS Corp (UTHR) filed a Annual Report (10-K) with the SEC on February 21, 2024. United Therapeutics Corp reported its fiscal year 2023 results.
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• FMR LLC & Abigail Johnson Trim United Therapeutics Stake to 4.939% — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in United Therapeutics Corp (UTHR). As of Dece
• United Therapeutics Amends Celularity Stake Disclosure — SC 13G/A · Feb 8, 2024 Risk: low
  United Therapeutics Corp. filed an amended Schedule 13G/A on February 8, 2024, indicating a change in their beneficial ownership of Celularity Inc. common stock
• Wellington Mgmt Amends United Therapeutics Stake on Dec 29 — SC 13G/A · Feb 8, 2024 Risk: low
  Wellington Management Group LLP filed an amended SC 13G/A on February 8, 2024, indicating a change in their ownership of United Therapeutics Corp's common stock
• BlackRock Amends United Therapeutics Stake, Signals Continued Holding — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership stake in UNITED THERAPEUTICS Corp as of December 31, 2023. Th

Frequently Asked Questions